|Many years ago, when we first started working with emerging life sciences companies to provide a roadmap for the commercialization of their technologies, we began with a list of essential activities and the corresponding budget that would be required. Our approach has always been to ensure those activities are synchronized with the product’s regulatory and… Read the full article…|
Spotlight on Transitions
|This topic of “transition” came home to me (literally and figuratively) over the Thanksgiving holiday. With our adult kids returning, my husband and I decided it was time to have them go through their “bins” and throw out, donate, or take back with them, their childhood. The bins in question are tools we employed over… Read the full article…|
Are You Inspiring Inspiration?
|It’s no secret that the topic of commercialization can be quite tedious in most of the environments we all work. We live in a world of PowerPoint templates, changing teams, external vendors, timelines, budgets, and shiny-object-chasing executives (you know who you are). In most cases, though, the day to day routine and grind is not what… Read the full article…|
The Future Is Now
|Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO, Mark Levin, that we had an opportunity to define how the company vision, “Transcend the Limits of Medicine,”could be translated at the customer level. This was a once-in-a-career role. I was able to surround… Read the full article…|
Living in a Parallel Universe
|Launching a company and drug simultaneously. (What follows is a synopsis of a recent “team development call,” something that occurs at The NemetzGroup over Zoom every other week. During these calls, we select a topic that allows us to enhance our learning, share best practices, and improve our client offerings.) We began by stating the… Read the full article…|
Tales from the Community… Our Readers Speak!
|This e-conversation goes out to about 2,000 people from the industry, our team’s network, and my life. (Thank you LinkedIn.) Over the course of publishing, we have heard from many of you on a broad range of topics. What we have found fascinating is that different topics generate interest with different people (welcome to the… Read the full article…|
Tales from the Healthcare Front Lines
|Each month, you have given our team permission to communicate our views on the biopharma industry, its leadership, and overall commercialization of innovative medicines. We share this perspective with knowledge of a healthcare system based on what we read, hear, and know from personal experience. In our industry, we often talk about innovation, technology, data,… Read the full article…|
Rare Diseases: Abandon Everything You Think You Know
|“Overcoming the hurdles has built a great faith in me that things can be done to help people with rare diseases. It will drive my optimism forever and my belief in achieving things that seem impossible.” —Henri Termeer, CEO of Genzyme,who launched the first lifesaving treatment, Ceredase, for Gaucher Disease I am and will always… Read the full article…|
Does Boston Biotech Have a Career Navigation Problem?
|For those of us who have been in the industry since pre-DRG days, and have the wisdom and experience across the industry, there are many opportunities to mentor and network with today’s emerging generation of biotech executives. Now and then, we get the chance to speak with those who truly are the future generation –… Read the full article…|
Four Essential Market Assessment Questions
|What follows are excerpts from a conversation among NemetzGroup team members regarding market assessment approaches. Specifically, we talked about the levels and types of market assessments needed to answer fundamental development and financial opportunity questions. The framework we tend to follow is shown below. For today’s newsletter, we will focus on the first column —… Read the full article…|